Johnson & Johnson is renaming its Alzheimer's disease drug Reminyl (galantamine HBr). Although the company and the FDA have not agreed on the new name, the change is expected to be introduced by the end of March 2005. The decision to change Reminyl's name comes after 2 patients died when they were mistakenly given a similar-sounding drugAmaryl (glimepiride). Amaryl (Sanofi-Aventis) is indicated for the treatment of diabetes. The deaths were caused by hypoglycemia or low blood sugar when the patients were given Amaryl.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs